JLPC(SH:600513) Zheng Quan Ri Bao Wang·2025-06-23 01:50Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is advancing its innovative drug LH-1801, which is expected to enter the market in 2026 if clinical trials proceed smoothly [1][2]. Company Summary - LH-1801 is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor designed to lower blood sugar by preventing glucose reabsorption in the kidneys, thus reducing the risk of hypoglycemia [1]. - The drug has successfully completed Phase I clinical trials and has been granted exemption from Phase II trials, moving directly to Phase III due to its favorable pharmacokinetic properties and safety profile [2]. - The Phase III clinical study is being conducted across over 70 top hospitals in China, led by a prominent endocrinology expert, ensuring scientific rigor [2]. Industry Summary - Diabetes has become a significant health threat, with a large and growing patient base in China [3]. - The Chinese type 2 diabetes pharmaceutical market is projected to grow at a compound annual growth rate (CAGR) of 10.18% from 2025 to 2030, reaching a market size of 151.8 billion yuan by 2025 and potentially expanding to 259.2 billion yuan by 2030 [3]. - SGLT-2 inhibitors represent a shift in diabetes treatment from merely controlling blood sugar to providing comprehensive cardiovascular and renal protection, making them a core recommendation in global treatment guidelines [3].